Metformin in Pregnancy: Mechanisms and Clinical Applications
AbstractMetformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy. The Metformin in Gestational Diabetes (MiG) RCT changed practice in many countries demonstrating that metformin had similar pregnancy outcomes to insulin therapy with less maternal weight gain and a high degree of patient acceptability. A multicentre RCT is currently assessing the addition of metformin to insulin in pregnant women with type 2 diabetes. RCT evidence is also available for the use of metformin in pregnancy for women with Polycystic Ovarian Syndrome and for nondiabetic women with obesity. No evidence of an increase in congenital malformations or miscarriages has been observed even when metformin is started before pregnancy and continued to term. Body composition and metabolic outcomes at two, seven, and nine years have now been reported for the offspring of mothers treated in the MiG study. In this review, we will briefly discuss the action of metformin and then consider the evidence from the key clinical trials. View Full-Text
Share & Cite This Article
Hyer, S.; Balani, J.; Shehata, H. Metformin in Pregnancy: Mechanisms and Clinical Applications. Int. J. Mol. Sci. 2018, 19, 1954.
Hyer S, Balani J, Shehata H. Metformin in Pregnancy: Mechanisms and Clinical Applications. International Journal of Molecular Sciences. 2018; 19(7):1954.Chicago/Turabian Style
Hyer, Steve; Balani, Jyoti; Shehata, Hassan. 2018. "Metformin in Pregnancy: Mechanisms and Clinical Applications." Int. J. Mol. Sci. 19, no. 7: 1954.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.